Lipid Nanoparticle Delivery Alters The Adjuvanticity of The TLR9 Agonist Cpg by Innate Immune Activation in Lymphoid Tissue
Zifu Zhong,Yong Chen,Kim Deswarte,Heleen Lauwers,Emily De Lombaerde,Xiaole Cui,Simon Van Herck,Tingting Ye,Mark Gontsarik,Stefan Lienenklaus,Niek N. Sanders,Bart N. Lambrecht,Stefaan De Koker,Bruno G. De Geest
DOI: https://doi.org/10.1002/adhm.202301687
IF: 10
2023-10-01
Advanced Healthcare Materials
Abstract:Pharmacological strategies to activate innate immune cells are of great relevance in the context of vaccine design and anti‐cancer immune therapy, to mount broad immune responses able to clear infection and malignant cells. Synthetic CpG oligodeoxynucleotides (CpG‐ODNs) are short single‐stranded DNA molecules containing unmethylated CpG dinucleotides and a phosphorothioate backbone. Class B CpG ODNs activate robust innate immune responses through a TLR9‐dependent NF‐κB signaling pathway. This feature is attractive to exploit in the context of vaccine design and cancer immunotherapy. Soluble CpG‐ODNs cause hepatic toxicity, which reduces its therapeutic applicability. We report on the formulation of class B CpG ODN1826 in lipid nanoparticles (LNPs) containing an ionizable cationic lipid that complexes CpG through electrostatic interaction. Upon local administration, LNP‐formulated CpG drains to lymph nodes and triggers robust innate immune activation. Unformulated, soluble, CpG, by contrast, is unable to induce robust innate activation in draining lymph nodes and is distributed systemically. In a vaccination setting, LNP‐formulated CpG, admixed with a protein antigen, induces higher antigen‐specific antibody titers and T cell responses than antigen admixed with unformulated soluble CpG. This article is protected by copyright. All rights reserved
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials